Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Mutual Drug-Drug Interaction Potential Between Denifanstat and Resmetirom in Healthy Adult Participants

Next Previous
Trial Profile

A Phase 1, Open-Label Study to Evaluate the Mutual Drug-Drug Interaction Potential Between Denifanstat and Resmetirom in Healthy Adult Participants

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denifanstat (Primary) ; Resmetirom (Primary)
  • Indications Acne vulgaris; Astrocytoma; Breast cancer; Glioblastoma; Liver cancer; Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Non-small cell lung cancer; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Sagimet Biosciences

Most Recent Events

  • 16 Oct 2025 Status changed from recruiting to active, no longer recruiting.
  • 14 Oct 2025 Status changed from planning to recruiting.
  • 22 May 2025 According to a Sagimet Biosciences media release, company will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET and the event will provide an overview of the planned Phase 1 pharmacokinetic clinical trial of the denifanstat and resmetirom combination, and a discussion on the potential benefits of combination therapy to treat patients living with advanced MASH.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top